Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 194

The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.

Targeting the p53 signaling pathway in cancer therapy – the promises, challenges and perils

Open access
Stegh, Alexander H·2012·Expert Opinion on Therapeutic Targets

Abstract

INTRODUCTION: Research over the past three decades has identified p53 as a multi-functional transcription factor. p53 influences myriad, highly diverse cellular processes, and represents one of the most important and extensively studied tumor suppressors. Activated by various stresses, p53 blocks cancer progression by provoking transient or permanent growth arrest, by enabling DNA repair, or by advancing cellular death programs. This anti-cancer activity profile, together with genomic and mutational analyses documenting inactivation of p53 in more than 50% of human cancers, motivated drug development efforts to (re-) activate p53 in established tumors. AREAS COVERED: The complexities of p53 signaling in cancer are summarized, including current strategies and challenges to restore p53's tumor suppressive function in established tumors, to inactivate p53 inhibitors, and to restore wild type function of p53 mutant proteins. EXPERT OPINION: p53 represents an attractive target for the development of anti-cancer therapies. Whether p53 is 'druggable', however, remains an area of active research and discussion, as p53 has pro-survival functions and chronic p53 activation accelerates aging, which may compromise the long-term homeostasis of an organism. The complex biology and dual functions of p53 in cancer prevention and age-related cellular responses pose significant challenges to the development of p53-targeting cancer therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1517/14728222.2011.643299

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 56 references

Research works printed but not linked: 137

  1. Vousden KH, 2007, Nat Rev Mol Cell Biol, 8, 275, 10.1038/nrm2147 · DOI · Paper page
  2. Lane DP, 1979, Nature, 278, 261, 10.1038/278261a0 · DOI · Paper page
  3. 10.1016/0092-8674(82)90356-7 · DOI · Paper page
  4. Werness BA, 1990, Science, 248, 76, 10.1126/science.2157286 · DOI · Paper page
  5. Scheffner M, 1990, Cell, 63, 1129, 10.1016/0092-8674(90)90409-8 · DOI · Paper page
  6. 10.1101/cshperspect.a001016 · DOI · Paper page
  7. Yonish-Rouach E, 1991, Nature, 352, 345, 10.1038/352345a0 · DOI · Paper page
  8. Clarke AR, 1993, Nature, 362, 849, 10.1038/362849a0 · DOI · Paper page
  9. Lowe SW, 1993, Cell, 74, 957, 10.1016/0092-8674(93)90719-7 · DOI · Paper page
  10. Sheikh MS, 1998, Cancer Res, 58, 1593
  11. Peter ME, 2003, Cell Death Differ, 10, 26, 10.1038/sj.cdd.4401186 · DOI · Paper page
  12. Ehrhardt H, 2008, Oncogene, 27, 783, 10.1038/sj.onc.1210666 · DOI
  13. Attardi LD, 2000, Genes Dev, 14, 704, 10.1101/gad.14.6.704 · DOI · Paper page
  14. Davies L, 2009, J Cell Mol Med, 13, 1995, 10.1111/j.1582-4934.2008.00590.x · DOI
  15. Stegh AH, 2001, Cardiol Clin, 19, 13, 10.1016/S0733-8651(05)70192-2 · DOI
  16. Youle RJ, 2008, Nat Rev Mol Cell Biol, 9, 47, 10.1038/nrm2308 · DOI · Paper page
  17. Miyashita T, 1995, Cell, 80, 293, 10.1016/0092-8674(95)90513-8 · DOI · Paper page
  18. Yu J, 2001, Mol Cell, 7, 673, 10.1016/S1097-2765(01)00213-1 · DOI · Paper page
  19. Nakano K, 2001, Mol Cell, 7, 683, 10.1016/S1097-2765(01)00214-3 · DOI · Paper page
  20. Han J, 2001, Proc Natl Acad Sci USA, 98, 11318, 10.1073/pnas.201208798 · DOI · Paper page
  21. 10.1126/science.284.5411.156 · DOI · Paper page
  22. Jeffers JR, 2003, Cancer Cell, 4, 321, 10.1016/S1535-6108(03)00244-7 · DOI · Paper page
  23. Chipuk JE, 2003, Cancer Cell, 4, 371, 10.1016/S1535-6108(03)00272-1 · DOI · Paper page
  24. Caelles C, 1994, Nature, 370, 220, 10.1038/370220a0 · DOI · Paper page
  25. Johnson TM, 2008, Proc Natl Acad Sci USA, 105, 1215, 10.1073/pnas.0706764105 · DOI
  26. Chipuk JE, 2005, Science, 309, 1732, 10.1126/science.1114297 · DOI · Paper page
  27. Mihara M, 2003, Mol Cell, 11, 577, 10.1016/S1097-2765(03)00050-9 · DOI · Paper page
  28. Leu JI, 2004, Nat Cell Biol, 6, 443, 10.1038/ncb1123 · DOI · Paper page
  29. 10.4161/cc.7.18.6759 · DOI
  30. Stegh AH, 2008, Proc Natl Acad Sci USA, 105, 10703, 10.1073/pnas.0712034105 · DOI
  31. Stegh AH, 2007, Genes Dev, 21, 98, 10.1101/gad.1480007 · DOI
  32. Stegh AH, 2010, Genes Dev, 24, 2194, 10.1101/gad.1924710 · DOI
  33. 10.4161/cc.10.1.14365 · DOI
  34. Kumar S, 2009, Nat Rev Cancer, 9, 897, 10.1038/nrc2745 · DOI
  35. Tinel A, 2004, Science, 304, 843, 10.1126/science.1095432 · DOI · Paper page
  36. Lin Y, 2000, Nat Genet, 26, 122, 10.1038/79102 · DOI · Paper page
  37. Zong WX, 2006, Genes Dev, 20, 1, 10.1101/gad.1376506 · DOI · Paper page
  38. Yuan J, 2010, Genes Dev, 24, 2592, 10.1101/gad.1984410 · DOI · Paper page
  39. Tu HC, 2009, Proc Natl Acad Sci USA, 106, 1093, 10.1073/pnas.0808173106 · DOI
  40. Giono LE, 2006, J Cell Physiol, 209, 13, 10.1002/jcp.20689 · DOI · Paper page
  41. Sherr CJ, 1994, Cell, 79, 551, 10.1016/0092-8674(94)90540-1 · DOI · Paper page
  42. el-Deiry WS, 1994, Cancer Res, 54, 1169
  43. el-Deiry WS, 1993, Cell, 75, 817, 10.1016/0092-8674(93)90500-P · DOI · Paper page
  44. Waldman T, 1995, Cancer Res, 55, 5187
  45. Rohaly G, 2005, Cell, 122, 21, 10.1016/j.cell.2005.04.032 · DOI
  46. St Clair S, 2004, Mol Cell, 16, 725, 10.1016/j.molcel.2004.11.002 · DOI · Paper page
  47. Hermeking H, 1997, Mol Cell, 1, 3, 10.1016/S1097-2765(00)80002-7 · DOI · Paper page
  48. Ando T, 2001, J Biol Chem, 276, 42971, 10.1074/jbc.M106460200 · DOI · Paper page
  49. Zhan Q, 1999, Oncogene, 18, 2892, 10.1038/sj.onc.1202667 · DOI · Paper page
  50. Jin S, 2000, J Biol Chem, 275, 16602, 10.1074/jbc.M000284200 · DOI · Paper page
  51. Nezi L, 2009, Curr Opin Cell Biol, 21, 785, 10.1016/j.ceb.2009.09.007 · DOI · Paper page
  52. Cross SM, 1995, Science, 267, 1353, 10.1126/science.7871434 · DOI · Paper page
  53. Di Leonardo A, 1997, Cancer Res, 57, 1013
  54. Fukasawa K, 1996, Science, 271, 1744, 10.1126/science.271.5256.1744 · DOI · Paper page
  55. 10.1128/MCB.18.2.1055 · DOI · Paper page
  56. Smith ML, 1994, Science, 266, 1376, 10.1126/science.7973727 · DOI · Paper page
  57. Smith ML, 1996, Oncogene, 13, 2255
  58. Janus F, 1999, Cell Mol Life Sci, 55, 12, 10.1007/s000180050266 · DOI
  59. Gottlieb E, 2010, Cold Spring Harb Perspect Biol, 2, a001040, 10.1101/cshperspect.a001040 · DOI · Paper page
  60. Ma W, 2007, J Bioenerg Biomembr, 39, 243, 10.1007/s10863-007-9083-0 · DOI
  61. Kulawiec M, 2009, J Carcinog, 8, 8, 10.4103/1477-3163.50893 · DOI
  62. Lebedeva MA, 2009, Biochim Biophys Acta, 1787, 328, 10.1016/j.bbabio.2009.01.004 · DOI · Paper page
  63. Okamura S, 1999, Oncol Res, 11, 281
  64. Schwartzenberg-Bar-Yoseph F, 2004, Cancer Res, 64, 2627, 10.1158/0008-5472.CAN-03-0846 · DOI · Paper page
  65. Kawauchi K, 2008, Nat Cell Biol, 10, 611, 10.1038/ncb1724 · DOI · Paper page
  66. Bensaad K, 2007, Trends Cell Biol, 17, 286, 10.1016/j.tcb.2007.04.004 · DOI · Paper page
  67. Li H, 2009, J Biol Chem, 284, 1748, 10.1074/jbc.M807821200 · DOI
  68. Vousden KH, 2009, Biochem Soc Trans, 37, 511, 10.1042/BST0370511 · DOI
  69. Muniyappa H, 2009, J Biol Chem, 284, 17069, 10.1074/jbc.M109.008557 · DOI
  70. Budanov AV, 2004, Science, 304, 596, 10.1126/science.1095569 · DOI · Paper page
  71. Cano CE, 2009, Cancer Res, 69, 219, 10.1158/0008-5472.CAN-08-2320 · DOI
  72. Hayflick L, 1965, Exp Cell Res, 37, 614, 10.1016/0014-4827(65)90211-9 · DOI · Paper page
  73. Zilfou JT, 2009, Cold Spring Harb Perspect Biol, 1, a001883, 10.1101/cshperspect.a001883 · DOI · Paper page
  74. Gorgoulis VG, 2003, EMBO J, 22, 1567, 10.1093/emboj/cdg157 · DOI
  75. Dumble M, 2007, Blood, 109, 1736, 10.1182/blood-2006-03-010413 · DOI · Paper page
  76. Junttila MR, 2010, Nature, 468, 567, 10.1038/nature09526 · DOI · Paper page
  77. Feldser DM, 2010, Nature, 468, 572, 10.1038/nature09535 · DOI · Paper page
  78. 10.1093/carcin/23.12.2011 · DOI · Paper page
  79. 10.1002/(SICI)1097-0215(19960917)67:6<808::AID-IJC9>3.0.CO;2-V · doi:10.1002/(sici)1097-0215(19960917)67:6<808::aid-ijc9>3.0.co;2-v
  80. Gomez-Manzano C, 1996, Cancer Res, 56, 694
  81. Gomez-Manzano C, 1997, J Natl Cancer Inst, 89, 1036, 10.1093/jnci/89.14.1036 · DOI
  82. 10.1097/00006123-199911000-00016 · DOI
  83. Li H, 1999, Clin Cancer Res, 5, 637
  84. Lang FF, 2003, J Clin Oncol, 21, 2508, 10.1200/JCO.2003.11.138 · DOI · Paper page
  85. 10.1158/1078-0432.CCR-09-1044 · DOI
  86. Zeimet AG, 2003, Lancet Oncol, 4, 415, 10.1016/S1470-2045(03)01139-2 · DOI · Paper page
  87. Nemunaitis J, 2000, Cancer Res, 60, 6359
  88. Shi J, 2009, Curr Opin Mol Ther, 11, 547
  89. 10.1007/s00432-009-0701-6 · DOI
  90. Tian G, 2009, Anticancer Drugs, 20, 389, 10.1097/CAD.0b013e32832a2df9 · DOI
  91. 10.1158/1535-7163.MCT-07-0125 · DOI
  92. 10.3892/or_00001018 · DOI
  93. Pan JJ, 2009, J Clin Oncol, 27, 799, 10.1200/JCO.2008.18.9670 · DOI
  94. Li Y, 2009, Clin Cancer Res, 15, 6724, 10.1158/1078-0432.CCR-09-1296 · DOI
  95. Keedy V, 2008, J Clin Oncol, 26, 4166, 10.1200/JCO.2007.15.6927 · DOI
  96. Ulasov IV, 2007, Hum Gene Ther, 18, 118, 10.1089/hum.2006.146 · DOI
  97. Bischoff JR, 1996, Science, 274, 373, 10.1126/science.274.5286.373 · DOI · Paper page
  98. Khuri FR, 2000, Nat Med, 6, 879, 10.1038/78638 · DOI · Paper page
  99. O'Shea CC, 2004, Cancer Cell, 6, 611, 10.1016/j.ccr.2004.11.012 · DOI · Paper page
  100. Chiocca EA, 2004, Mol Ther, 10, 958, 10.1016/j.ymthe.2004.07.021 · DOI · Paper page
  101. 10.2174/156800907780058862 · DOI
  102. Tyler MA, 2009, Gene Ther, 16, 262, 10.1038/gt.2008.165 · DOI
  103. 10.1634/stemcells.2007-0758 · DOI · Paper page
  104. Sherr CJ, 2006, Nat Rev Cancer, 6, 663, 10.1038/nrc1954 · DOI · Paper page
  105. 10.4161/cc.3.4.801 · DOI · Paper page
  106. Kojima K, 2005, Blood, 106, 3150, 10.1182/blood-2005-02-0553 · DOI · Paper page
  107. Secchiero P, 2009, Blood, 113, 4300, 10.1182/blood-2008-11-187708 · DOI
  108. Carter BZ, 2010, Blood, 115, 306, 10.1182/blood-2009-03-212563 · DOI
  109. Galatin PS, 2004, J Med Chem, 47, 4163, 10.1021/jm034182u · DOI
  110. Lu Y, 2006, J Med Chem, 49, 3759, 10.1021/jm060023+ · DOI
  111. Yin H, 2005, Angew Chem Int Ed Engl, 44, 2704, 10.1002/anie.200462316 · DOI · Paper page
  112. 10.1158/1535-7163.MCT-05-0199 · DOI · Paper page
  113. Essmann F, 2011, Br J Pharmacol
  114. Hardcastle IR, 2011, J Med Chem, 54, 1233, 10.1021/jm1011929 · DOI
  115. 10.1021/jm0601194 · DOI
  116. 10.4161/cc.1.6.259 · DOI
  117. Sur S, 2009, Proc Natl Acad Sci USA, 106, 3964, 10.1073/pnas.0813333106 · DOI · Paper page
  118. 1998, Crit Rev Immunol, 18, 29, 10.1615/CritRevImmunol.v18.i1-2.40 · DOI
  119. 10.1158/1078-0432.CCR-08-2227 · DOI · Paper page
  120. 10.1038/onc.2008.249 · DOI
  121. Bykov VJ, 2005, J Biol Chem, 280, 30384, 10.1074/jbc.M501664200 · DOI · Paper page
  122. Wiman KG, 2010, Oncogene, 29, 4245, 10.1038/onc.2010.188 · DOI · Paper page
  123. Boeckler FM, 2008, Proc Natl Acad Sci USA, 105, 10360, 10.1073/pnas.0805326105 · DOI · Paper page
  124. 10.1101/sqb.2005.70.049 · DOI
  125. Demma M, 2010, J Biol Chem, 285, 10198, 10.1074/jbc.M109.083469 · DOI
  126. Kravchenko JE, 2008, Proc Natl Acad Sci USA, 105, 6302, 10.1073/pnas.0802091105 · DOI · Paper page
  127. North S, 2002, Mol Carcinog, 33, 181, 10.1002/mc.10038 · DOI
  128. Weinmann L, 2008, Cell Death Differ, 15, 718, 10.1038/sj.cdd.4402301 · DOI
  129. Belyi VA, 2010, Cold Spring Harb Perspect Biol, 2, a001198, 10.1101/cshperspect.a001198 · DOI · Paper page
  130. 10.1038/onc.2010.266 · DOI
  131. Saddler C, 2008, Blood, 111, 1584, 10.1182/blood-2007-09-112698 · DOI
  132. Calabro V, 2004, Mol Cell Biol, 24, 8529, 10.1128/MCB.24.19.8529-8540.2004 · DOI
  133. 10.1074/jbc.C600147200 · DOI · Paper page
  134. Wang H, 2011, Mol Cancer Ther, 10, 69, 10.1158/1535-7163.MCT-10-0581 · DOI · Paper page
  135. Issaeva N, 2004, Nat Med, 10, 1321, 10.1038/nm1146 · DOI · Paper page
  136. Smith MA, 2011, Pediatr Blood Cancer
  137. Bernal F, 2007, J Am Chem Soc, 129, 2456, 10.1021/ja0693587 · DOI · Paper page

Cited by

See all 194

Metadata

Authors
Stegh, A. H.
Venue
Expert Opinion on Therapeutic Targets
Published
2012-01
Volume
16
Issue
1
Pages
67-83
ISSN
  • 1472-8222 (ISSN-L)
  • 1744-7631
OpenAlex
W1980250100
Cited by
194
References
56
FWCI
7.53
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting the p53 signaling pathway in cancer therapy – the promises, challenges and perils. https://app.cochat.ai/papers/10.1517/14728222.2011.643299
The paper
Stegh, A. H. (2012). Targeting the p53 signaling pathway in cancer therapy – the promises, challenges and perils. Expert Opinion on Therapeutic Targets. https://doi.org/10.1517/14728222.2011.643299

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.